interleukin-2

interleukin-2 is a cytokine and a crucial signaling molecule in the immune system. It is primarily produced by activated T cells and plays a central role in the proliferation and differentiation of immune cells. Its discovery marked a pivotal moment in immunology, leading to significant advances in both basic science and clinical medicine.

Structure and function

The molecule is a small protein with a four-helix bundle structure, a common motif among many hematopoietic cytokines. It functions by binding to a high-affinity receptor complex expressed on the surface of target cells, which includes the CD25 subunit. Its primary physiological role is to stimulate the growth and activity of T lymphocytes and natural killer cells, which are essential for mounting effective adaptive immune responses. It also plays a key role in the development and function of regulatory T cells, which are critical for maintaining immune tolerance and preventing autoimmunity.

Clinical applications

It was one of the first immunotherapies approved for clinical use, specifically for the treatment of metastatic renal cell carcinoma and metastatic melanoma. The therapy, often administered at high doses, demonstrated the potential of harnessing the immune system to fight cancer, a concept foundational to modern oncology. However, its use is limited by significant toxicity, including a condition known as capillary leak syndrome. Research efforts, including those at the National Cancer Institute, have since focused on developing safer, engineered versions and combination regimens.

Mechanism of action

The biological effects are mediated through its interaction with a specific cell surface receptor composed of three subunits: CD25, CD122, and CD132. This binding triggers intracellular signaling cascades, primarily the JAK-STAT pathway, involving proteins like JAK1, JAK3, STAT5, and the PI3K/AKT pathway. These signals promote cell cycle progression and the expression of genes critical for cell proliferation and survival. The differential expression of the receptor subunits on various cell types, such as effector T cells versus regulatory T cells, allows it to exert both stimulatory and regulatory functions.

Discovery and history

The activity was first described in the 1970s by researchers, including Doris Morgan and Robert Gallo, who identified a factor that could support the long-term growth of T cells in culture. This factor was subsequently purified and its gene cloned in the early 1980s by teams at the Genentech Corporation and the Immunology Branch of the National Cancer Institute. The pioneering clinical trials led by Steven Rosenberg at the National Institutes of Health in the 1980s established its potential as an antineoplastic agent. This work laid the groundwork for the entire field of cancer immunotherapy.

Research and future directions

Current investigations are focused on creating engineered variants with improved therapeutic windows, such as molecules designed to selectively expand regulatory T cells for treating autoimmune disorders like type 1 diabetes. Another major area involves its use in arming CAR-T cells to enhance their persistence and efficacy against hematological malignancies. Furthermore, research into superagonist molecules and fusion proteins that target the cytokine to specific tissues or tumor microenvironments is actively pursued by institutions like the Memorial Sloan Kettering Cancer Center and the University of California, San Francisco.

Category:Immune system Category:Cytokines Category:Oncology